Full-Time
Posted on 6/27/2024
Develops treatments for neurodegenerative diseases
Senior, Expert
Remote in USA
Must reside and work within the United States in a state where Amylyx currently does business.
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.
Company Stage
IPO
Total Funding
$548.9M
Headquarters
Cambridge, Massachusetts
Founded
2013
Help us improve and share your feedback! Did you find this helpful?